Movers and SHAKERS
Filament Health (FLHLF)
FY2021 Reported With A Review Of Clinical Pipeline Progress
Filament Health Corp is a natural psychedelic drug discovery and extraction technology company. Its mission is to see safe, approved, natural psychedelics in the hands of everyone who needs them as soon as possible. Filament engages in natural extraction technology commercialization, utilizing its intellectual property portfolio, in-house GMP facility, and Health Canada psilocybin Dealer's License.
Robert LeBoyer, Vice President, Research Analyst, Life Sciences, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Filament Made Substantial Progress During 4Q21. Filament Health reported a full year loss of $9.3 million or $(0.06) per share. During the quarter, Filament advanced its clinical pipeline, made licensing agreements, and strengthened its intellectual property. The cash balance at December 31, 2021 was $4.6 million.
Clinical Trials Have Begun. During 4Q, Filament announced regulatory clearance for its first clinical trial. This trial began patient treatment in March 2022, testing its naturally-derived psilocybin and its bioactive form, psilocin. The trial has three arms to compare the standard doses of oral psilocybin (PEX010), oral psilocin (PEX020), and sublingual psilocin (PEX030) ...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.